15504-60-6 Usage
Description
CHEMBRDG-BB 5762406 is a benzodiazepine derivative with the molecular formula C26H30N6O3 and a molecular weight of 474.55 g/mol. It selectively acts as a high affinity partial agonist at the α5 subtype of the GABAA receptor, exhibiting anxiolytic and anticonvulsant properties in preclinical studies. Its unique pharmacological profile indicates potential therapeutic benefits with reduced sedative and cognitive impairing effects compared to traditional benzodiazepines, positioning it as a promising candidate for the development of new treatments for anxiety and epilepsy.
Uses
Used in Pharmaceutical Industry:
CHEMBRDG-BB 5762406 is used as a potential anxiolytic agent for the treatment of anxiety disorders. Its selective action on the α5 subtype of the GABAA receptor suggests that it may provide therapeutic benefits with reduced sedative and cognitive side effects compared to traditional benzodiazepines.
Used in Neurological Disorders Research:
CHEMBRDG-BB 5762406 is used as a potential anticonvulsant agent for the treatment of epilepsy and other seizure disorders. Its demonstrated anticonvulsant properties in preclinical studies make it a promising candidate for further research and development in the field of central nervous system disorders.
Used in Drug Development:
CHEMBRDG-BB 5762406 is used as a target for the development of new treatments for anxiety and epilepsy. Its unique pharmacological profile and potential therapeutic benefits make it a valuable compound for further research and development in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 15504-60-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,5,0 and 4 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 15504-60:
(7*1)+(6*5)+(5*5)+(4*0)+(3*4)+(2*6)+(1*0)=86
86 % 10 = 6
So 15504-60-6 is a valid CAS Registry Number.
InChI:InChI=1/C12H15NO2/c14-11-6-4-5-10(9-11)12(15)13-7-2-1-3-8-13/h4-6,9,14H,1-3,7-8H2
15504-60-6Relevant articles and documents
A preparation method for rosacea acetate hydrochloride
-
Paragraph 0105-0106, (2021/12/07)
The present invention relates to the field of pharmaceutical preparation technology, in particular to a method for preparing rosatidine acetate hydrochloride. The present invention adopts m-hydroxybenzoic acid as a starting material, a wide range of sources, inexpensive, and it can be prepared by oxidation of m-hydroxytoluene, without involving a toxicity warning structure and nitrosamine impurities; at the same time, in this preparation process only involves a genotoxic warning structure substance, reducing the risk of medication of subsequent drugs.
Enantioselective synthesis of atropisomeric benzamides through peptide-catalyzed bromination
Barrett, Kimberly T.,Miller, Scott J.
supporting information, p. 2963 - 2966 (2013/04/10)
We report the enantioselective synthesis of atropisomeric benzamides employing catalytic electrophilic aromatic substitution reactions involving bromination. The catalyst is a simple tetrapeptide bearing a tertiary amine that may function as a Br?nsted base. A series of tri- and dibrominations were accomplished for a range of compounds bearing differential substitution patterns. Tertiary benzamides represent appropriate substrates for the reaction since they exhibit sufficiently high barriers to racemization after ortho functionalization. Mechanism-driven experiments provided some insight into the basis for selectivity. Examination of the observed products at low conversion suggested that the initial catalytic bromination may be regioselective and stereochemistry-determining. A complex between the catalyst and substrate was observed by NMR spectroscopy, revealing a specific association. Finally, the products of these reactions may be subjected to regioselective metal-halogen exchange and trapping with I2, setting the stage for utility.
